RTW.L | Ticker Profile - Titan Protect

RTW.L

RTW Biotech Opportunities Ltd

Financial Services · Asset Management · LSE

$2.15

Data: 2026-05-28

✗ ETHICAL FAIL

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$699M

Total market value of the company

Trailing P/E

3.43

Very cheap relative to earnings

Forward P/E

N/A

Based on estimated future earnings — lower means cheaper

Rev Growth

-10.0%

Year-over-year revenue change

Profit Margin

709.2%

How much profit the company keeps from each dollar of revenue

ROE

32.7%

Return on equity — how efficiently it uses shareholder money

Analyst Target

N/A

Recommendation

NONE

Consensus view from ? analysts covering this stock

About RTW Biotech Opportunities Ltd

RTW Biotech Opportunities Ltd is a venture capital fund. The fund specializes in directly investing and early-stage. The fund specializes in identifying transformative assets with high growth potential across the life sciences, biopharmaceutical and medical technology sectors. The fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.

https://www.rtwfunds.com/rtw-biotech-opportunities-ltd

Country: United States Industry: Asset Management

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

FAIL

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% N/A

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.988

Good returns relative to risk taken

Kelly Fraction

-0.1044

No positive edge detected — the data suggests staying out

Calmar Ratio

0.659

Acceptable balance between returns and drawdown risk

Annual Return

24.0%

Historical annualised return based on price data

Max Drawdown

-36.3%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

437

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.78

Less volatile than the market — more defensive

52W High

$2.32

7% below the year high

52W Low

$1.13

90% above the year low

Avg Volume

679,660

Average daily shares traded — higher means easier to buy and sell

Short Ratio

N/A

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$0.63

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

1.66

Healthy liquidity position

Quick Ratio

0.62

Like current ratio but excludes inventory — stricter test

Gross Margin

100.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-43.6%

Profit from core operations before interest and tax

Free Cash Flow

$-73,144,560

Negative — the business is spending more than it generates

Revenue (TTM)

$35M

Total revenue over the last 12 months

Net Income

$245M

Profitable — the bottom line is positive

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go